231 related articles for article (PubMed ID: 33051396)
1. [Treatment of Multiple Sclerosis, Neuromyelitis Optica Spectrum Disorder and Myasthenia Gravis during the COVID-19 Pandemic].
Nakamura M; Nakashima I
Brain Nerve; 2020 Oct; 72(10):1079-1083. PubMed ID: 33051396
[TBL] [Abstract][Full Text] [Related]
2. COVID-19 in Refractory Myasthenia Gravis- A Case Report of Successful Outcome.
Ramaswamy SB; Govindarajan R
J Neuromuscul Dis; 2020; 7(3):361-364. PubMed ID: 32508329
[TBL] [Abstract][Full Text] [Related]
3. Changes in patient and physician attitudes resulting from COVID-19 in neuromyelitis optica spectrum disorder and multiple sclerosis.
Salama S; Giovannoni G; Hawkes CH; Lechner-Scott J; Waubant E; Levy M
Mult Scler Relat Disord; 2020 Jul; 42():102259. PubMed ID: 32571580
[No Abstract] [Full Text] [Related]
4. Management of central nervous system demyelinating diseases during the coronavirus disease 2019 pandemic: a practical approach.
ApÓstolos-Pereira SL; Silva GD; Disserol CCD; Feo LB; Matos AMB; Schoeps VA; Gomes ABAGR; Boaventura M; Mendes MF; Callegaro D
Arq Neuropsiquiatr; 2020 Jul; 78(7):430-439. PubMed ID: 32609290
[TBL] [Abstract][Full Text] [Related]
5. The impact of COVID-19 on patients with neuromyelitis optica spectrum disorder; a pilot study.
Tomczak A; Han MH
Mult Scler Relat Disord; 2020 Oct; 45():102347. PubMed ID: 32645636
[TBL] [Abstract][Full Text] [Related]
6. Risk of COVID-19 infection in MS and neuromyelitis optica spectrum disorders.
Fan M; Qiu W; Bu B; Xu Y; Yang H; Huang D; Lau AY; Guo J; Zhang MN; Zhang X; Yang CS; Chen J; Zheng P; Liu Q; Zhang C; Shi FD
Neurol Neuroimmunol Neuroinflamm; 2020 Sep; 7(5):. PubMed ID: 32503092
[TBL] [Abstract][Full Text] [Related]
7. Neuromyelitis optica spectrum disorder secondary to COVID-19.
Shaw VC; Chander G; Puttanna A
Br J Hosp Med (Lond); 2020 Sep; 81(9):1-3. PubMed ID: 32990089
[No Abstract] [Full Text] [Related]
8. Respiratory dysfunction as first presentation of myasthenia gravis misdiagnosed as COVID-19.
Scopelliti G; Osio M; Arquati M; Pantoni L
Neurol Sci; 2020 Dec; 41(12):3419-3421. PubMed ID: 33068195
[TBL] [Abstract][Full Text] [Related]
9. Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.
Möhn N; Pul R; Kleinschnitz C; Prüss H; Witte T; Stangel M; Skripuletz T
Front Immunol; 2020; 11():1059. PubMed ID: 32477373
[TBL] [Abstract][Full Text] [Related]
10. COVID-19 in teriflunomide-treated patients with multiple sclerosis.
Maghzi AH; Houtchens MK; Preziosa P; Ionete C; Beretich BD; Stankiewicz JM; Tauhid S; Cabot A; Berriosmorales I; Schwartz THW; Sloane JA; Freedman MS; Filippi M; Weiner HL; Bakshi R
J Neurol; 2020 Oct; 267(10):2790-2796. PubMed ID: 32494856
[TBL] [Abstract][Full Text] [Related]
11. Considerations for the Treatment of Inflammatory Neuro-Ophthalmologic Disorders During the COVID-19 Pandemic.
Martin Paez Y; Bennett JL; Subramanian PS; Pelak VS
J Neuroophthalmol; 2020 Sep; 40(3):305-314. PubMed ID: 32804456
[TBL] [Abstract][Full Text] [Related]
12. Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic.
Brownlee W; Bourdette D; Broadley S; Killestein J; Ciccarelli O
Neurology; 2020 Jun; 94(22):949-952. PubMed ID: 32241953
[No Abstract] [Full Text] [Related]
13. Screening neuromyelitis optica patients for COVID-19 infection.
Mirmosayyeb O; Vaheb S; Barzegar M; Shaygannejad V; Bonavita S; Ghajarzadeh M
Autoimmun Rev; 2020 Nov; 19(11):102669. PubMed ID: 32942032
[No Abstract] [Full Text] [Related]
14. Clinical Reasoning: Therapeutic considerations in myasthenic crisis due to COVID-19 infection.
Hoang P; Hurtubise B; Muppidi S
Neurology; 2020 Nov; 95(18):840-843. PubMed ID: 32817186
[No Abstract] [Full Text] [Related]
15. Management of patients with generalised myasthenia gravis and COVID-19: four case reports.
Hübers A; Lascano AM; Lalive PH
J Neurol Neurosurg Psychiatry; 2020 Oct; 91(10):1124-1125. PubMed ID: 32651248
[No Abstract] [Full Text] [Related]
16. Immunocompromised myasthenia gravis patient not infected with SARS-CoV-2 after close exposure - what is the risk of COVID-19?
Rzepiński Ł; Wawrzyniak S; Maciejek Z
Neurol Neurochir Pol; 2020; 54(5):481-482. PubMed ID: 33006133
[No Abstract] [Full Text] [Related]
17. Merits and culprits of immunotherapies for neurological diseases in times of COVID-19.
Pawlitzki M; Zettl UK; Ruck T; Rolfes L; Hartung HP; Meuth SG
EBioMedicine; 2020 Jun; 56():102822. PubMed ID: 32535547
[TBL] [Abstract][Full Text] [Related]
18. Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.
; Jacob S; Muppidi S; Guidon A; Guptill J; Hehir M; Howard JF; Illa I; Mantegazza R; Murai H; Utsugisawa K; Vissing J; Wiendl H; Nowak RJ
J Neurol Sci; 2020 May; 412():116803. PubMed ID: 32247193
[No Abstract] [Full Text] [Related]
19. Speculative clues on Myasthenia gravis and COVID-19.
Scoppetta C; Casciato S; Di Gennaro G
Eur Rev Med Pharmacol Sci; 2020 Aug; 24(15):7925-7926. PubMed ID: 32767317
[No Abstract] [Full Text] [Related]
20. Exacerbation of chronic inflammatory demyelinating polyneuropathy in concomitance with COVID-19.
Abu-Rumeileh S; Garibashvili T; Ruf W; Fangerau T; Kassubek J; Althaus K; Otto M; Senel M
J Neurol Sci; 2020 Nov; 418():117106. PubMed ID: 32911389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
